Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

Next Previous
Trial Profile

A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft Versus Host Disease After at Least 2 Prior Lines of Systemic Therapy

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axatilimab (Primary) ; Ciclosporin; Everolimus; Ibrutinib; Imatinib; Mycophenolate mofetil; Pentostatin; Proteasome inhibitors; Rituximab; Sirolimus; Tacrolimus
  • Indications Graft-versus-host disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Incyte Corporation

Most Recent Events

  • 03 Jun 2025 According to an Incyte corporation media release, data from the study will be presented at the 2025 European Hematology Association (EHA) congress, held June 12 -15, 2025, in Milan.
  • 21 May 2025 Status changed from not yet recruiting to recruiting.
  • 20 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top